ERBB2 and cancer: As somatic mutations in cancer driver genes and metabolic dysregulation are intimately linked to the progression and therapeutic responsiveness of HR+/HER2– BC (27), we next delineated the discrepancies in somatic mutational profiles between the tumors with and without KIFC2 amplification in the FUSCC (27), TCGA, and METABRIC data sets.